Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cytokinetics

37.66
-0.6830-1.78%
Volume:799.45K
Turnover:30.55M
Market Cap:4.51B
PE:-7.36
High:39.12
Open:38.37
Low:37.58
Close:38.34
52wk High:59.39
52wk Low:29.31
Shares:119.66M
Float Shares:119.09M
Volume Ratio:0.66
T/O Rate:0.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.1182
EPS(LYR):-5.2646
ROE:-572.15%
ROA:-24.87%
PB:-12.22
PE(LYR):-7.15

Loading ...

Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2025

THOMSON REUTERS
·
Yesterday

Cytokinetics Inc. Files Initial Beneficial Ownership Statement for Director James M. Daly

Reuters
·
Aug 20

Cytokinetics names Jim Daly to Board of Directors

TIPRANKS
·
Aug 20

Cytokinetics Appoints Jim Daly to Board of Directors, Enhancing Commercial Expertise

Reuters
·
Aug 20

Fady Ibraham Malik, EVP of Research & Development, Reports Disposal of Common Shares in Cytokinetics Inc

Reuters
·
Aug 20

Cytokinetics Announces New Employee Compensation Plan with Stock Options and RSUs as Inducements

Reuters
·
Aug 20

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 20

Robert I. Blum, President & CEO, Reports Disposal of Common Shares in Cytokinetics Inc

Reuters
·
Aug 16

Cytokinetics (CYTK) Gets a Buy from Mizuho Securities

TIPRANKS
·
Aug 16

Stock Track | Cytokinetics Soars 5.03% Following Analyst's Buy Rating and $57 Price Target

Stock Track
·
Aug 13

Stock Track | Cytokinetics Soars 5.03% as Analyst Reiterates Buy Rating with $57 Price Target

Stock Track
·
Aug 13

Cytokinetics: Promising Outlook with Aficamten’s Regulatory Progress and Strong Financial Health

TIPRANKS
·
Aug 12

Analysts Offer Insights on Healthcare Companies: Omada Health, Inc. (OMDA), Gilead Sciences (GILD) and Cytokinetics (CYTK)

TIPRANKS
·
Aug 11

Cytokinetics Is Maintained at Buy by Citigroup

Dow Jones
·
Aug 09

Buy Rating for Cytokinetics Driven by Regulatory Reviews and Strategic Trials for Drug Afi

TIPRANKS
·
Aug 09

Cytokinetics Shares up 2% After Q2 Results

THOMSON REUTERS
·
Aug 08

BUZZ-Cytokinetics rises as investors await US approval for heart drug

Reuters
·
Aug 08

RBC Capital Reaffirms Their Buy Rating on Cytokinetics (CYTK)

TIPRANKS
·
Aug 08

Piper Sandler Sticks to Its Buy Rating for Cytokinetics (CYTK)

TIPRANKS
·
Aug 08

Cytokinetics (CYTK) Receives a Buy from Morgan Stanley

TIPRANKS
·
Aug 08